New York State Teachers Retirement System Sells 1,500 Shares of Innoviva, Inc. (NASDAQ:INVA)

New York State Teachers Retirement System decreased its position in shares of Innoviva, Inc. (NASDAQ:INVA) by 2.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,946 shares of the biotechnology company’s stock after selling 1,500 shares during the period. New York State Teachers Retirement System owned approximately 0.10% of Innoviva worth $1,177,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of INVA. EdgeRock Capital LLC purchased a new stake in shares of Innoviva during the second quarter valued at $31,000. Bessemer Group Inc. boosted its stake in shares of Innoviva by 333.5% during the first quarter. Bessemer Group Inc. now owns 2,211 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 1,701 shares during the period. Innealta Capital LLC purchased a new stake in shares of Innoviva during the second quarter valued at $33,000. GAMMA Investing LLC boosted its stake in shares of Innoviva by 53.7% during the second quarter. GAMMA Investing LLC now owns 3,476 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,214 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in shares of Innoviva during the first quarter valued at $138,000. Institutional investors own 99.12% of the company’s stock.

Analyst Upgrades and Downgrades

INVA has been the subject of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Innoviva in a research note on Tuesday, July 30th. StockNews.com lowered shares of Innoviva from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 6th.

Innoviva Stock Up 0.9 %

NASDAQ:INVA opened at $20.18 on Friday. The firm has a market cap of $1.26 billion, a PE ratio of 29.25 and a beta of 0.57. The company has a 50-day moving average of $19.61 and a 200 day moving average of $17.81. Innoviva, Inc. has a 1-year low of $13.31 and a 1-year high of $20.37. The company has a debt-to-equity ratio of 0.67, a current ratio of 12.70 and a quick ratio of 11.40.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.